Pulmonary hypertension in patients with chronic myeloproliferative disorders.
Pulmonary hypertension (PH) is a major complication of several haematological disorders. Chronic myeloproliferative diseases (CMPDs) associated with pulmonary hypertension have been included in group five of the clinical classification for pulmonary hypertension, corresponding to pulmonary hypertension for which the aetiology is unclear and/or multifactorial. The aim of this review is to discuss the epidemiology, pathogenic mechanism and treatment approaches of the more common forms of pulmonary hypertension in the context of CMPD's: chronic thromboembolic pulmonary hypertension, precapillary pulmonary hypertension and drug-induced PH.
Pulmonary Division, Carmel Medical Center, Faculty of Medicine, Technion, Institute of Technology, Haifa, Israel adir-sh@zahav.net.il.
Yochai
Y
Adir
U.O. di Pneumologia e Terapia Semi-Intensiva, Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe, MultiMedica IRCSS, Milan, Italy.
Davide
D
Elia
U.O. di Pneumologia e Terapia Semi-Intensiva, Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe, MultiMedica IRCSS, Milan, Italy.
Sergio
S
Harari
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D062186:Arterial Pressure / Q000187:drug effects; D002908:Chronic Disease; D004691:Endarterectomy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D009196:Myeloproliferative Disorders / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011651:Pulmonary Artery / Q000187:drug effects / Q000503:physiopathology* / Q000601:surgery; D018570:Risk Assessment; D012307:Risk Factors; D013923:Thromboembolism / Q000209:etiology; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D047428:Protein Kinase Inhibitors